
AstraZeneca's flagship Tagrisso helps lung cancer patients live longer in pivotal study
AstraZeneca is off to a good start in August. After its PARP inhibitor Lynparza scored in a prostate cancer trial earlier this week, the British drugmaker on Friday disclosed that its star cancer drug Tagrisso helped patients with a certain type of lung cancer live longer in a late-stage study.
The overall survival data follows positive progression-free survival data unveiled in 2017 from the FLAURA Phase III trial involving patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). AstraZeneca estimates roughly 10-15% of patients in the US and Europe, and 30-40% of patients in Asia have EGFR-mutated NSCLC.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.